Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.AIDS Community Research Initiative of America (ACRIA) - Spring 2006
25 years after AIDS was first identified, development of new drugs has seen a sudden upsurge. While only one new drug was approved in the last two years, a number of compounds are now moving into advanced trials, offering new hope for people who have become resistant to many of the approved HIV medications
In this issue of ACRIA Update, a number of seasoned HIV treatment activists present the "inside story" on the development of HIV drugs, from both activist and personal perspectives. And we're pleased that former ACRIA staffer Donna Kaminski has weighed in with news from a recent AIDS conference.
Of course, taking any experimental treatment comes with risks, including the risk of adding only one new drug to a failing regimen. ACRIA has always urged anyone who is thinking of joining a clinical trial, either here at ACRIA or at any trial site, to discuss all their options with their health care provider, and to carefully weigh all the pros and cons in order to make a fully informed decision.
With this issue, I am also pleased to introduce myself as ACRIA's new Executive Director. Committed to finding effective and safe treatment for HIV disease, and ultimately a cure for AIDS, I am very excited to join ACRIA. After 11 years under the skilled leadership of J Daniel Stricker, ACRIA is well-positioned to lead this battle and bring new attention to the fight against AIDS - both in treatment and HIV health literacy.
As a long-time advocate for underserved communities, working with the Coalition for the Homeless, Housing Works, and as Director of Housing Opportunities for Persons with AIDS (HOPWA) at the Postgraduate Center for Mental Health, I am especially proud to join an organization committed to HIV treatment access and educational services for marginalized populations.
I welcome your comments and insights and look forward to working with you in the fight against AIDS.
20060301
CR060301
Copyright © 2006 - AIDS Community Research Initiative of America. Reproduction of this article (other than one copy for personal reference) must be cleared through the Editor, ACRIA Update, 230 West 38th Street, 17th Floor, New York, NY 10018; (212) 924-3934; Fax (212) 924-3936 .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. ÆGIS. All materials appearing on ÆGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content.